A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Desidustat (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Cadila Healthcare
- 22 Apr 2021 Status changed from active, no longer recruiting to completed.
- 25 Jan 2021 Results presented in a Zydus media release.
- 11 Dec 2020 Planned End Date changed from 30 Jan 2021 to 28 Feb 2021.